EGFR and non-small cell lung carcinoma: The mutations of EGFR observed in NSCLC were not consistently observed in TNBC cases, which directs us to follow protocols where the EGFR gene copy number [110], mutations in exon 19 and exon 21, and EGFR gene expression are needed to be assessed rather than only EGFR mutational analysis to define the patient's eligibility for GEF treatment.